Pfizer and BioNTech have announced positive results in the Phase 2/3 trial for two Omicron-adapted versions of their mRNA vaccine. One candidate vaccine is monovalent targets the spike protein of the Omicron BA. 1 variant, while the other is a bivalent combination of the first candidate and Pfizer and BioNTech’s previous COVID-19 vaccine.
According to Fleur Jeffries, “The phase 2/3 trial involved 1,234 participants aged 56 and older. One month after receiving a booster dose, the Omicron-adapted monovalent candidates significantly increased protection against Omicron BA.1, showing a 13.5 and 19.6-fold increase above pre-booster dose levels.”
To learn more, click here.
(Source: PM Live, June 27th, 2022)